Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 5/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16574155 | 0.78 | TP53 (0.43) | PDE10ACYP11B2CYP11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20032453 | 0.72 | FGFR1 (0.50) | CYP11B2CYP11B1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23840290 | 0.68 | PDE10A (0.45) | PDE10ACYP11B2CYP11B1KMORECQL | |
| SCHEMBL29496843 | 0.68 | NPC1 (0.61) | PDE10ACYP11B2CYP11B1RECQLSMN1; SMN2 | |
| SCHEMBL30032844 | 0.67 | HPGD (0.54) | CYP11B2CYP11B1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5335838 | 0.66 | HDAC8 (0.42) | PDE10ACYP11B2CYP11B1KMORECQL | |
| SCHEMBL20628028 | 0.65 | SMO (0.32) | CYP11B2CYP11B1SMO | |
| SCHEMBL20032439 | 0.65 | KDM4E (0.44) | ALDH1A1KCNH2RAB9A | |
| SCHEMBL2546320 | 0.65 | TSHR (0.46) | PDE10ACYP11B2CYP11B1RECQLSMN1; SMN2 | |
| SCHEMBL14688369 | 0.65 | CYP11B1 (0.40) | PDE10ACYP11B2CYP11B1KMORECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PDE10A 3809/4885CYP11B2 105/4885CYP11B1 54/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PDE10A 3809/4885CYP11B2 105/4885CYP11B1 54/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PDE10A 3809/4885CYP11B2 105/4885CYP11B1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.